

## Sprint Bioscience Q1 2023 - VADA deal needed

Redeye provides its comment on Sprint Bioscience's Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Sprint Bioscience Q1 2023 - VADA deal needed](#)